Cargando…
RARE-28. The use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review
Current strategies for managing craniopharyngioma result in significant morbidity. Successful treatment with interferon alfa(INFα) after progression is reported in the literature. This retrospective review details our institutional experience with INFα in craniopharyngioma patients. Method: Between...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164804/ http://dx.doi.org/10.1093/neuonc/noac079.053 |
_version_ | 1784720225391869952 |
---|---|
author | Patil, Prabhumallikarjun Gray, Rachel Goldman-Yassen, Adam Aguilera, Dolly Castellino, Robert Janss, Anna Mazewski, Claire |
author_facet | Patil, Prabhumallikarjun Gray, Rachel Goldman-Yassen, Adam Aguilera, Dolly Castellino, Robert Janss, Anna Mazewski, Claire |
author_sort | Patil, Prabhumallikarjun |
collection | PubMed |
description | Current strategies for managing craniopharyngioma result in significant morbidity. Successful treatment with interferon alfa(INFα) after progression is reported in the literature. This retrospective review details our institutional experience with INFα in craniopharyngioma patients. Method: Between 2000-2021, we treated 81 craniopharyngioma patients. Twenty-two patients received 26 treatment courses of subcutaneous INFα. Twenty-three courses were evaluable for response. Results: Ten patients received upfront INFα after cyst decompression +/- ommaya placement. Progression free survival(PFS) ranged between 7-38mo. Three patients continue on treatment (10+, 12+, 14+mo); seven progressed (four on treatment (7, 9, 25, 38mo), three after treatment (13, 19, 32mo)). At progression, three underwent surgery alone, three underwent surgery and radiation, one resumed INFα. Thirteen patients received INFα after progression. Prior to INFα, eight patients had had surgery, five surgery and radiation. Two in each group had INFα, previously. PFS ranged between 5-82+mo. One patient remains on treatment (5+mo); four continue in follow-up without progression (23+,40+,64+,82+mo) with two patients avoiding radiation to date; eight progressed (three on treatment (6-8mo), five after treatment (16,24,26,46,71mo)). At progression, two underwent surgery alone, three underwent surgery and radiation, one received re-irradiation, two resumed INFα. While receiving INFα, two patients experienced serious adverse events (one intra-tumoral hemorrhage (not attributed to INFα), one suicidal ideation). Both recovered. One tolerated retreatment with INFα. Three additional patients stopped INFα for intolerance, but two received INFα at subsequent progression. No other unanticipated side effects were reported. Conclusion: INFα therapy in patients with both newly diagnosed and progressive craniopharyngioma delayed the need for aggressive surgical resection and/or radiotherapy in some cases. In some patients, INFα resulted in prolonged stabilization of disease delaying or avoiding radiation. Overall, INFα side effects were manageable. These results are encouraging regarding INFα therapy for patients with craniopharyngioma and warrant further evaluation with a clinical trial. |
format | Online Article Text |
id | pubmed-9164804 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-91648042022-06-05 RARE-28. The use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review Patil, Prabhumallikarjun Gray, Rachel Goldman-Yassen, Adam Aguilera, Dolly Castellino, Robert Janss, Anna Mazewski, Claire Neuro Oncol Craniopharyngioma and Rare Tumors Current strategies for managing craniopharyngioma result in significant morbidity. Successful treatment with interferon alfa(INFα) after progression is reported in the literature. This retrospective review details our institutional experience with INFα in craniopharyngioma patients. Method: Between 2000-2021, we treated 81 craniopharyngioma patients. Twenty-two patients received 26 treatment courses of subcutaneous INFα. Twenty-three courses were evaluable for response. Results: Ten patients received upfront INFα after cyst decompression +/- ommaya placement. Progression free survival(PFS) ranged between 7-38mo. Three patients continue on treatment (10+, 12+, 14+mo); seven progressed (four on treatment (7, 9, 25, 38mo), three after treatment (13, 19, 32mo)). At progression, three underwent surgery alone, three underwent surgery and radiation, one resumed INFα. Thirteen patients received INFα after progression. Prior to INFα, eight patients had had surgery, five surgery and radiation. Two in each group had INFα, previously. PFS ranged between 5-82+mo. One patient remains on treatment (5+mo); four continue in follow-up without progression (23+,40+,64+,82+mo) with two patients avoiding radiation to date; eight progressed (three on treatment (6-8mo), five after treatment (16,24,26,46,71mo)). At progression, two underwent surgery alone, three underwent surgery and radiation, one received re-irradiation, two resumed INFα. While receiving INFα, two patients experienced serious adverse events (one intra-tumoral hemorrhage (not attributed to INFα), one suicidal ideation). Both recovered. One tolerated retreatment with INFα. Three additional patients stopped INFα for intolerance, but two received INFα at subsequent progression. No other unanticipated side effects were reported. Conclusion: INFα therapy in patients with both newly diagnosed and progressive craniopharyngioma delayed the need for aggressive surgical resection and/or radiotherapy in some cases. In some patients, INFα resulted in prolonged stabilization of disease delaying or avoiding radiation. Overall, INFα side effects were manageable. These results are encouraging regarding INFα therapy for patients with craniopharyngioma and warrant further evaluation with a clinical trial. Oxford University Press 2022-06-03 /pmc/articles/PMC9164804/ http://dx.doi.org/10.1093/neuonc/noac079.053 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Craniopharyngioma and Rare Tumors Patil, Prabhumallikarjun Gray, Rachel Goldman-Yassen, Adam Aguilera, Dolly Castellino, Robert Janss, Anna Mazewski, Claire RARE-28. The use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review |
title | RARE-28. The use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review |
title_full | RARE-28. The use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review |
title_fullStr | RARE-28. The use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review |
title_full_unstemmed | RARE-28. The use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review |
title_short | RARE-28. The use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review |
title_sort | rare-28. the use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review |
topic | Craniopharyngioma and Rare Tumors |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164804/ http://dx.doi.org/10.1093/neuonc/noac079.053 |
work_keys_str_mv | AT patilprabhumallikarjun rare28theuseofsubcutaneousinterferoninpatientswithcraniopharyngiomaaninstitutionalretrospectivereview AT grayrachel rare28theuseofsubcutaneousinterferoninpatientswithcraniopharyngiomaaninstitutionalretrospectivereview AT goldmanyassenadam rare28theuseofsubcutaneousinterferoninpatientswithcraniopharyngiomaaninstitutionalretrospectivereview AT aguileradolly rare28theuseofsubcutaneousinterferoninpatientswithcraniopharyngiomaaninstitutionalretrospectivereview AT castellinorobert rare28theuseofsubcutaneousinterferoninpatientswithcraniopharyngiomaaninstitutionalretrospectivereview AT janssanna rare28theuseofsubcutaneousinterferoninpatientswithcraniopharyngiomaaninstitutionalretrospectivereview AT mazewskiclaire rare28theuseofsubcutaneousinterferoninpatientswithcraniopharyngiomaaninstitutionalretrospectivereview |